Type 2 diabetes is the most common major form of diabetes and is characterised by a progressive inability to maintain normal glucose regulation, typically involving insulin resistance together with inadequate compensatory insulin secretion. Insulin resistance means that tissues such as skeletal muscle, liver and adipose tissue respond less effectively to insulin. The pancreas initially attempts to compensate by secreting more insulin, but in susceptible individuals beta-cell function progressively becomes insufficient.
Glucose consequently rises in the fasting state, after meals, or both. Unlike type 1 diabetes, type 2 diabetes is not primarily defined by autoimmune destruction of beta cells. Unlike gestational diabetes, it is not restricted to pregnancy. It is a heterogeneous metabolic disorder whose severity and underlying mechanisms vary considerably between individuals. The American Diabetes Association defines it as a non-autoimmune progressive loss of adequate beta-cell insulin secretion, frequently occurring against a background of insulin resistance.
Insulin resistance involves several interconnected physiological abnormalities. In skeletal muscle, insulin normally stimulates glucose uptake, but resistance reduces this response, leaving more glucose in circulation after meals. In the liver, insulin normally suppresses glucose production, whereas hepatic insulin resistance allows excessive gluconeogenesis and glycogen breakdown, contributing to elevated fasting glucose. Adipose tissue insulin resistance can increase release of free fatty acids, which can further disturb insulin signalling and beta-cell function.
The pancreas may compensate by increasing insulin secretion, producing hyperinsulinaemia during earlier stages. Over time, however, beta cells may lose functional capacity, and glucose levels become progressively abnormal. This progression explains why type 2 diabetes can develop gradually through a period of insulin resistance and prediabetes before crossing the diagnostic threshold. It also explains why treatment may need to become more intensive over time even when a person maintains consistent lifestyle habits.
Risk factors for type 2 diabetes include age, family history, excess body weight, physical inactivity, previous gestational diabetes and certain population-level genetic and social factors. The NHS specifically identifies ethnicity, age, overweight or obesity and family history among factors associated with higher risk. However, type 2 diabetes is not synonymous with obesity: people with lower body weight can develop it, while many people with obesity do not develop diabetes. Genetics can strongly influence beta-cell resilience, fat distribution and insulin sensitivity.
Sleep disorders, chronic stress, some medications and other metabolic conditions can also influence glucose regulation. Risk should therefore be understood probabilistically rather than as a simple checklist of causes. The presence or absence of one characteristic does not establish whether an individual will develop type 2 diabetes, and diagnosis still requires appropriate glucose or HbA1c testing rather than risk-factor assessment alone.
Type 2 diabetes can remain undiagnosed for years because hyperglycaemia may initially be modest and symptoms can be absent or nonspecific. When symptoms do develop, they can include increased thirst, frequent urination, fatigue, blurred vision and unexplained weight loss, but these manifestations may be less dramatic than in rapidly developing type 1 diabetes. Chronic hyperglycaemia can nevertheless cause progressive vascular and neurological damage while the person feels relatively well. This is why screening and risk-based testing are important.
Prediabetes, defined by intermediate abnormalities such as HbA1c 5.7–6.4%, fasting plasma glucose 5.6–6.9 mmol/L or two-hour glucose 7.8–11.0 mmol/L under ADA criteria, is not equivalent to established diabetes but indicates increased future risk. The transition is not inevitable, and lifestyle and medical interventions can reduce progression risk.
Treatment of type 2 diabetes is individualised and commonly begins with measures addressing nutrition, physical activity and weight where appropriate. These interventions can improve insulin sensitivity and reduce glucose exposure, but many people eventually require medication because type 2 diabetes is a progressive metabolic disorder. Metformin is widely used and reduces blood glucose partly by reducing hepatic glucose production and improving insulin sensitivity.
Other drug classes include sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 therapies, dipeptidyl peptidase-4 inhibitors, sulfonylureas, thiazolidinediones and insulin, with selection depending on glucose-lowering requirements, cardiovascular and renal considerations, weight effects, adverse effects, cost and other factors. The NHS identifies lifestyle treatment, metformin and insulin among established treatment approaches.
Type 2 diabetes differs from type 1 diabetes in its usual mechanism, but the distinction is not always obvious from one clinical feature. Type 2 is generally non-autoimmune and associated with insulin resistance, whereas type 1 is usually autoimmune and characterised by progressive beta-cell destruction. Some adults with autoimmune diabetes can initially be misclassified as having type 2, particularly when onset is gradual. Conversely, some people with type 2 diabetes become sufficiently insulin deficient to require insulin therapy.
Therefore, treatment with insulin does not itself prove that someone has type 1 diabetes, and the need for medication does not indicate that type 2 diabetes has somehow “become” type 1. Where classification is uncertain, clinicians can use autoantibody testing, C-peptide and longitudinal clinical information alongside standard glucose measurements to clarify the underlying disease process.
Long-term type 2 diabetes management involves more than controlling glucose. Persistent hyperglycaemia can contribute to retinopathy, kidney disease, neuropathy, foot complications and cardiovascular disease, while hypertension and abnormal lipid levels can independently increase cardiovascular risk. Consequently, clinical care commonly includes HbA1c monitoring, blood pressure assessment, cholesterol management, kidney testing, eye screening and foot assessment. Medication selection increasingly considers cardiovascular and renal protection as well as glucose lowering.
SGLT2 inhibitors, for example, have roles extending beyond glucose reduction in selected people with cardiovascular or chronic kidney disease, while GLP-1 receptor agonist-based treatments can have effects on weight and cardiovascular outcomes in appropriate populations. These therapeutic distinctions demonstrate why modern type 2 diabetes treatment cannot be reduced to a single universal medication or glucose target.
Type 2 diabetes can sometimes be prevented or delayed in people at elevated risk, unlike established type 1 diabetes for which ordinary lifestyle measures are not considered preventive treatment. Evidence supports physical activity, healthier dietary patterns and appropriate weight management as important measures for reducing progression from prediabetes to type 2 diabetes. The WHO recommends at least 150 minutes of moderate physical activity each week as part of prevention guidance.
However, prevention should not be framed as assigning blame: genetic susceptibility, age, socioeconomic factors, medications, previous gestational diabetes and other biological influences affect risk. Type 2 diabetes can also be substantially improved through treatment and lifestyle intervention after diagnosis, but “reversal” has a specific clinical meaning and should not be confused with a permanent cure. A person whose glucose returns to the non-diabetic range without glucose-lowering medication may still require continued monitoring because the underlying susceptibility can persist.
